![The F-35’s future: What new weapons, systems are coming to the stealth fighter? [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/09/8603513-scaled-e1725629281248.jpg?#)
Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith
Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but analysts are keeping faith in the gene therapy’s wider safety profile.
Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but analysts are keeping faith in the gene therapy’s wider safety profile.
